The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias-Reference-Cited by-同舟云学术

The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias

Published:2018-07-01 Issue:13 Volume:57 Page:1827-1832
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Fujita Tetsuo¹,Hiroishi Takuma¹,Shikano Kohei¹,Yanagisawa Asako¹,Hayama Noriko¹,Amano Hiroyuki¹,Nakamura Makoto¹,Hirano Satoshi²,Tabeta Hiroshi¹,Nakamura Sukeyuki¹

Affiliation:

1. Department of Respirology, Funabashi Municipal Medical Center, Japan

2. Department of Medical Oncology, Funabashi Municipal Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/13/57_0404-17/_pdf

Reference36 articles.

1. 1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.

2. 2. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18: 317-323, 2007.